[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Srivastava et al., 2024 - Google Patents

ADVANCEMENT OF NANOTECHNOLOGY IN CANCER BIOMARKER SCREENING

Srivastava et al., 2024

View PDF
Document ID
13834488816728175879
Author
Srivastava P
Mishra V
Publication year

External Links

Snippet

Cancer is an extremely complicated disease that spreads through a multi-step process that involves angiogenesis, resistance to apoptosis, unchecked cell growth, changes in cellular signalling, tissue invasion, and metastasis. The present review paper was based on the …
Continue reading at wjpr.s3.ap-south-1.amazonaws.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group

Similar Documents

Publication Publication Date Title
Dessale et al. Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosis
Zhang et al. Nanotechnology in cancer diagnosis: progress, challenges and opportunities
Barani et al. Nanodiagnosis and nanotreatment of colorectal cancer: An overview
Xing et al. DNA aptamer functionalized nanomaterials for intracellular analysis, cancer cell imaging and drug delivery
Barani et al. Nanotechnology in ovarian cancer: Diagnosis and treatment
Mohammadpour et al. Applications of two-dimensional nanomaterials in breast cancer theranostics
Sheikhpour et al. Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment
Sun et al. Progress in the research of nanomaterial-based exosome bioanalysis and exosome-based nanomaterials tumor therapy
Liu et al. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery
Wu et al. Aptamers: active targeting ligands for cancer diagnosis and therapy
Ye et al. ZnO-based nanoplatforms for labeling and treatment of mouse tumors without detectable toxic side effects
Kumar et al. Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging
Shi et al. Multifunctional biocompatible graphene oxide quantum dots decorated magnetic nanoplatform for efficient capture and two-photon imaging of rare tumor cells
He et al. Bioconjugated nanoparticles for DNA protection from cleavage
Xing et al. DNA aptamer technology for personalized medicine
Mokhtarzadeh et al. Aptamers as smart ligands for nano-carriers targeting
Stobiecka et al. Sensing of survivin mRNA in malignant astrocytes using graphene oxide nanocarrier-supported oligonucleotide molecular beacons
Bahreyni et al. A new chemotherapy agent-free theranostic system composed of graphene oxide nano-complex and aptamers for treatment of cancer cells
Stephen et al. Cancer nanotechnology in medicine: a promising approach for cancer detection and diagnosis
Fathi-Karkan et al. Biomedical applications of aptamer-modified chitosan nanomaterials: An updated review
PramaniK et al. Multifunctional hybrid graphene oxide for circulating tumor cell isolation and analysis
Lu et al. MnO2 nanotube-based nanoSearchlight for imaging of multiple microRNAs in live cells
Miao et al. Tetrahedral DNA mediated direct quantification of exosomes by contact-electrification effect
Shahdordizadeh et al. Aptamer application in targeted delivery systems for diagnosis and treatment of breast cancer
Peng et al. Silicon nanostructures for cancer diagnosis and therapy